Inorganic growth model becoming unsustainable, Accenture analysis suggests

An analysis from Accenture has suggested that biopharma’s inorganic approach to fostering growth is no longer sustainable due to rising M&A costs.

An increased focus on bio-platforms and capabilities such as artificial intelligence (AI) is needed to accelerate innovation, according to the research.

Biopharma companies have relied heavily on M&A for growth, with more than 60% of their marketed assets coming through acquisitions over the past 15 years.